Pharmaceutical firm Eisai Co. and its joint venture with Italy's Bracco SpA said Monday they will withdraw a new drug application for the contrast agent code-named E7155.
The decision was made because additional clinical data are necessary to complete the risk/benefit profile, Eisai and Bracco-Eisai Co. said in a joint statement.
E7155 is a gadolinium-based contrast agent for magnetic resonance imaging, which was licensed from Bracco Imaging SpA, the two companies said.
They said they are discussing a development plan for the product, which is currently being marketed in other countries.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.